“Biote’s third quarter revenue increased 12.8% from the prior-quarter period, driven by continued growth in procedure revenue and a strong return to growth in our dietary supplements business,” said ...
IRVING, Texas--(BUSINESS WIRE)-- Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today ...
Reports Q3 revenue $51.4M, consensus $51.4M. “Biote’s (BTMD) third quarter revenue increased 12.8% from the prior-quarter period, driven by continued growth in procedure revenue and a strong return to ...
Peterson stated, "we reiterate our fiscal 2025 revenue guidance of above $190 million and our fiscal 2025 adjusted EBITDA guidance of above $50 million." Management continues to expect mid-teens ...
IRVING, Texas--(BUSINESS WIRE)--Biote, a high growth, differentiated medical practice-building business within the hormone optimization space, today announced record financial results for the fourth ...
Reports Q4 revenue $49.8M, consensus $51.2M. “In 2024 Biote (BTMD) strengthened its capabilities to provide the next level of individualized and evidence-based healthcare,” said Bob Peterson, Biote ...
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a high growth, differentiated medical practice-building business within the hormone optimization space, today ...
biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today ...
biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results